Results 31 to 40 of about 22,997 (249)
Pharmaceutical lobbying in Brazil: a missing topic in the public health research agenda
Revista de Saúde PúblicaIn the US, where registration of lobbyists is mandatory, the pharmaceutical industry and private health-care providers spend huge amounts of money seeking to influence health policies and government decisions. In Brazil, where lobbying lacks transparency,
Francisco José Roma Paumgartten
doaj +1 more source
Regulation of Antimycin Biosynthesis Is Controlled by the ClpXP Protease
mSphere, 2020 The survival of any microbe relies on its ability to respond to environmental change. Use of extracytoplasmic function (ECF) RNA polymerase sigma (σ) factors is a major strategy enabling dynamic responses to extracellular signals.
Bohdan Bilyk +4 more
doaj +1 more source
Advanced Science, EarlyView.Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Pyruvate Dehydrogenase Kinase as a Novel Therapeutic Target in Oncology
Frontiers in Oncology, 2013 Current drug development in oncology is non-selective as it typically focuses on pathways essential for the survival of all dividing cells. The unique metabolic profile of cancer, which is characterized by increased glycolysis and suppressed ...
Gopinath eSutendra +1 more
doaj +1 more source
Advanced Science, EarlyView.Herein we report a boron‐based pyrazole, (Borsantrazole ‐ a small molecule that selectively targets oxidative stress) that significantly increases survival, reduces weight loss, delays disease onset, and affects global protein changes in the SOD1‐G37R mouse model of ALS.
Nitesh Sanghai +9 more
wiley +1 more source
Non-oncology orphan drug development: Productivity and probability of success
Drug Discovery TodayThere are >6000 rare diseases (RDs), affecting >300 million people worldwide. Despite increases in orphan drug designations (ODDs), approved treatments remain scarce. This study analyzes the outcomes of non-oncology ODs designated by the FDA and European Medicines Agency (EMA) in 2017, providing a 7-8-year window to evaluate progression.
Samantha Parker +6 more
openaire +3 more sources
Advanced Science, EarlyView.A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv +16 more
wiley +1 more source
Advanced Intelligent Discovery, EarlyView.Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova +4 more
wiley +1 more source
PharmaceuticsRecent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents.
Mohamed El-Tanani +6 more
doaj +1 more source
Orphan drugs: Unmet societal need for non-profitable privately supplied new products
Research Policy, 2007 Due to the severity of rare diseases, the societal need for biopharmaceutical treatments for these diseases is high, despite low numbers of patients. Therefore, we investigated the barriers currently hindering the willingness to develop orphan drugs in the Netherlands.
Moors, E.H.M., Faber, J.
openaire +3 more sources